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Background: In the present study, we used multimodal imaging to investigate biodistribution in rats after
intravenous administration of a new 99mTc-labeled delivery system consisting of polymer-shelled microbubbles
(MBs) functionalized with diethylenetriaminepentaacetic acid (DTPA), thiolated poly(methacrylic acid) (PMAA),
chitosan, 1,4,7-triacyclononane-1,4,7-triacetic acid (NOTA), NOTA-super paramagnetic iron oxide nanoparticles
(SPION), or DTPA-SPION.
Methods: Examinations utilizing planar dynamic scintigraphy and hybrid imaging were performed using a
commercially available single-photon emission computed tomography (SPECT)/computed tomography (CT) system.
For SPION containing MBs, the biodistribution pattern of 99mTc-labeled NOTA-SPION and DTPA-SPION MBs was
investigated and co-registered using fusion SPECT/CT and magnetic resonance imaging (MRI). Moreover, to
evaluate the biodistribution, organs were removed and radioactivity was measured and calculated as percentage of
injected dose.
Results: SPECT/CT and MRI showed that the distribution of 99mTc-labeled ligand-functionalized MBs varied with the
type of ligand as well as with the presence of SPION. The highest uptake was observed in the lungs 1 h post
injection of 99mTc-labeled DTPA and chitosan MBs, while a similar distribution to the lungs and the liver was seen
after the administration of PMAA MBs. The highest counts of 99mTc-labeled NOTA-SPION and DTPA-SPION MBs
were observed in the lungs, liver, and kidneys 1 h post injection. The highest counts were observed in the liver,
spleen, and kidneys as confirmed by MRI 24 h post injection. Furthermore, the results obtained from organ
measurements were in good agreement with those obtained from SPECT/CT.
Conclusions: In conclusion, microbubbles functionalized by different ligands can be labeled with radiotracers and
utilized for SPECT/CT imaging, while the incorporation of SPION in MB shells enables imaging using MR. Our
investigation revealed that biodistribution may be modified using different ligands. Furthermore, using a single
contrast agent with fusion SPECT/CT/MR multimodal imaging enables visualization of functional and anatomical
information in one image, thus improving the diagnostic benefit for patients.
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Multimodality imaging is becoming an essential tool in
diagnostics. Multimodality imaging provides functional
and anatomical data from different imaging techniques
such as single-photon emission computed tomography
(SPECT)/magnetic resonance imaging (MRI), SPECT/
computed tomography (CT) or positron emission tom-
ography (PET)/MRI to obtain the highest readout from
in vivo examination and hence increase clinical efficacy.
Poly(vinyl alcohol) (PVA) microbubbles (MBs) func-
tionalized with ligands are currently undergoing several
investigations worldwide as a potential contrast agent
[1-5] to facilitate diagnosis and visualize physiological
changes in diseases such as cancer, stroke, metabolic
disorders, inflammation, and ischemia [2,6-8]. The
functionalization of MBs by different ligands to incor-
porate superparamagnetic iron oxide nanoparticles
(SPION) makes them visible by multimodality imaging
techniques, thus enabling their use for diagnostic
purposes [9]. Incorporating SPION in the shells of MBs
facilitates their visualization by MRI, while func-
tionalization of MBs with ligands (which can incorporate
radioactive tracers) facilitates visualization using SPECT/
CT. Imaging techniques using SPECT/CT and MRI as
less invasive approaches for testing new drugs offer a
number of benefits. These include reducing the number
of laboratory animals used for research, increasing
reproducibility, and saving time and money [10]. More-
over, imaging techniques can visualize the distribution
and elimination of the contrast agents in vivo, which
can be utilized as a diagnostic tool to differentiate
between healthy and pathological tissues. The ligand-
functionalized MBs might therefore be of interest for
diagnostic imaging, including the diagnosis of cancer.
MBs also have the capability to act as a delivery vehicle
for drugs or cytostatic agents [11-13]. Several attempts
have been made to improve drug delivery systems in
order to enhance stability, pharmacokinetics, bioavail-
ability, and biodistribution for several compounds [14].
Moreover, drug delivery systems may minimize the ad-
verse effects of drugs by directing them to the target
organs.
SPECT has become a powerful tool for imaging the
biodistribution of molecules labeled with radioactive
isotopes such as 99mTc or 123I as a step in the early
stages of drug development [15-20]. SPECT offers func-
tional information, while CT and MRI offer anatomical
and physiological details. Combined SPECT/CT has
improved diagnostics since it enhances both sensitivity
and specificity. SPECT/CT has shown superiority in sev-
eral medical fields including the diagnosis of carcinoids,
brain tumors, lymphomas, prostate cancers, bone
lesions, and infections [21]. SPECT/CT has also led to a
better evaluation of therapeutic outcome in cardio-vascular as well as hepatic and renal impairment patients
[17,21].
The chelating ligand diethylenetriaminepentaacetic
acid (DTPA) in its pure form is rapidly cleared through
urine in healthy kidneys and is therefore often used to
quantify renal impairment [22]. 99mTc-DTPA kits are
commercially available for renal imaging and are used to
measure renal function and glomerular filtration rate. In
humans, the biological half-life of DTPA is 1 to 2 h and
renal uptake is 7% [14]. However, scant information is
available about the biodistribution and elimination of
DTPA-functionalized MBs.
In order to study the effect of ligands on biodistribution,
several ligands have been chosen to functionalize the MBs.
DTPA, 1,4,7-triacyclononane-1,4,7-triacetic acid (NOTA),
chitosan, thiolated poly(methacrylic acid) (PMAA) and
plain MBs were labeled with 99mTc and studied. These
ligands have the following properties: chitosan is a linear
polysaccharide with a backbone characterized by a ran-
dom distribution of β-(1-4)-linked D-glucosamine and N-
acetyl-D-glucosamine units. Chitosan is biocompatible, is
known to have good chelating capacity for metal ions, and
has previously been used as a nonviral gene delivery sys-
tem to the lungs [23-25]. NOTA is a monoreactive ligand
commonly used for tracer attachment in PET imaging and
has been used for imaging of tumors in the pancreas,
stomach, and adrenals [26]. PMAA may be used as a lig-
and on MBs to further improve the MBs coupling to other
moieties. It has been used to control shell functionality of
microspheres due to its biocompatibility [27,28].
SPION was incorporated between the layers of PVA
MBs followed by ligand coupling with DTPA or NOTA
to enable the multimodality imaging of MBs using
SPECT and MRI. In the current study, we imaged
NOTA-SPION and DTPA-SPION MBs using SPECT/
CT and MRI to visualize their biodistribution since
99mTc is also incorporated into the PVA matrix of MBs.
Little is known about the function, distribution, and
elimination of the ligands used to functionalize MBs in
this study, despite their previous use in the medical field.
The aim of the present study is to investigate the distri-
bution and elimination of ligand-functionalized MBs
using SPECT/CT and MRI in order to further develop
MBs as contrast agent for cancer diagnostics and detec-
tion of inflammation, and/or to evaluate their use in
multimodality imaging which might improve the diag-
nostic methods.
Methods
MBs were functionalized with several ligands, and their
in vivo distribution in rats was investigated using
SPECT/CT and MRI. The following aminoguanidine
(AG) MBs were studied: AGMBs (plain MBs), AGMBs/
DTPA (DTPA MBs), AGMBs/PMAA (PMAA MBs),
Figure 1 Production of MBs and quality control. The MBs were
washed in several steps (part I, A). MBs in the upper phase were
separated by centrifugation, isolating the plain MBs with a positively
charged surface. These MBs were then functionalized by different
ligands using the layer-by-layer technique (part I, B). As quality
control, DTPA-SPION MBs were visualized by the confocal laser
microscope (Leica, resolution 550 μm × 550 μm; part II), and flow
cytometry (Partec CyFlow ML flow cytometer) was used to
determine the size distribution of DTPA-MBs (part III) using forward
scattering versus side scattering dot plot.
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(NOTA-SPION MBs), and AGMB/DTPA-SPION (DTPA-
SPION MBs) obtained from Surflay Nanotec GmbH,
Berlin, Germany. Moreover, chitosan MBs were studied
and obtained from the Department of Chemical Sciences
and Technologies, University Tor Vergata, Rome, Italy.
The formation of microbubbles
PVA-shelled MB synthesis has been described elsewhere
[29]. The synthesis can be summarized as follows: 2 g
PVA at 70 K (P1763, Sigma-Aldrich Chemie GmbH,
Munich, Germany) was added to 100 mL of Milli-Q
water (Millipore Co., Billerica, MA, USA). The suspen-
sion was stirred at 80°C to allow PVA dissolution. Ap-
proximately 0.19 g of sodium metaperiodate was added
to the solution, and the mixture was stirred for 1 h at
80°C. The solution was cooled to room temperature,
with continuous stirring to avoid the formation of a PVA
film. The cross-linking reaction was then carried out
under vigorous stirring at room temperature for 2 h at
8,000 rpm by an Ultra-Turrax T-25 (IKA Works, Inc.,
Wilmington, NC, USA) equipped with a Teflon-coated
tip. Floating MBs were separated from solid debris and
extensively washed with Milli-Q water.
Aminoguanidine coupling
The MB suspension was centrifuged at 30×g for 1 h
followed by the removal of the subnatant. AG (5mg/mL)
in 0.1 M Hepes buffer (pH 8) was added, and the sus-
pension was kept on the shaker for 1 day.
Afterward, the MBs were washed three times. After each
wash, the MBs in the upper phase were separated by cen-
trifugation (30×g, 1 h), and the subnatant was removed.
Plain MBs with a positively charged surface (amino
groups) were obtained. The charged surface is necessary
to functionalize MBs by different ligands including DTPA,
PMAA, NOTA, NOTA-SPION, and DTPA-SPION (part I
of Figure 1). MBs were visualized using confocal laser mi-
croscopy at a resolution of 550 μm × 550 μm (part II of
Figure 1) (Leica TCS SPE, Leica Microsystems, Wetzlar,
Germany). Size distribution was determined using flow
cytometry (Partec CyFlow ML, Partec GmbH, Münster,
Germany). Analysis was carried out using forward
scattering versus side scattering. Part III of Figure 1 shows
DTPA-SPION MBs.
Preparation of DTPA MBs
The DTPA-isothiocyanate (0.2 mg DTPA/108 MBs) was
added to a suspension of AGMBs in 10 mM NaHCO3 at
pH 8. The reaction mixture was shaken overnight,
washed, and separated by centrifugation (30×g, 40 min).
Polyamines in the top layer of the MB surface react with
isothiocyanates at pH 8 to form a stable isothiourea
Figure 2 Chemical structures of the ligands DTPA and NOTA. The polyamines with the chelating ligand DTPA or NOTA react with
isothiocyanates at pH 8 to form a stable isothiourea bond in the molecule containing NOTA or DTPA.
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onto MBs (Figure 2).Preparation of NOTA MBs
NOTA-isothiocyanate (0.2 mg NOTA/108 MBs; Figure 2)
was added to a suspension of AGMBs in 10 mM
NaHCO3 at pH 8. The reaction mixture was shaken
overnight and washed as described previously.Chitosan oxidation
The metaperiodate ion, IO4
−, cleaves to the C2-C3 bond
of the glucosamine residue of chitosan, leading to the
formation of a dialdehyde with the elimination of an am-
monia molecule. However, the N-acetylated amino
groups (in small amounts) at the C2 position of the
chitosan backbone (15%) prevent the oxidation cleavage
by metaperiodate. For the oxidation reaction, chitosan
was dissolved in 1% (w/v) double-distilled water/HCl at
pH 4.5 and was thereafter mixed with a given amount of
NaIO4 (dark condition). A twofold molar excess of
chitosan in relation to NaIO4 was used. After 24 h, the
solution was dialyzed (dialysis membrane, MWCO of
2,000) against deionized water (pH 4.5), lyophilized, and
stored as a freeze-dried powder. The oxidation that leads
to chain depolymerization as a side reaction increased
the low solubility of chitosan in water and preven-
ted cluster formation of the MBs. The freeze-dried
periodate-oxidized chitosan was dissolved in D2O (5%
w/w trimethylsilanol (TMS)) at a concentration of 5 mg/
mL. The resulting solution was subjected to 1H-NMR
examination, and the degree of oxidation was calculated
considering the integral of the C2 resonance at 3.00ppm, taking as reference the signal of the trimethyl
group of TMS at 0.0 ppm (9H, TMS trimethyl group).
Oxidized chitosan coupling to the surface of MBs
The oxidized chitosan (Figure 3) is conjugated to MBs
by an acetylization procedure. The polymer is dissolved
in Milli-Q water to a concentration of 1% (w/v). A sam-
ple of 20-mg aqueous MB suspension was added, and
the final volume was adjusted to 10 mL. The pH was
carefully adjusted to 3.0 with 0.1 M HCl. The resulting
suspension was stirred in the dark for 5 days at room
temperature followed by extensive washing in separatory
funnels and stored in Milli-Q water at 4°C.
Preparation of PMAA MBs
The AGMBs were coated in standard PMAA (MW ap-
proximately 1 × 105 g/mol; Figure 3) solution at pH 6.2.
The reaction took approximately 1 day, and the reaction
mixture was washed as described previously under
DTPA preparation.
Preparation of magnetic microbubbles with NOTA (NOTA-
SPION MBs) or DTPA (DTPA-SPION MBs)
The AGMBs were coated by layers of polystyrene sulfon-
ate (PSS), polyethyleneimine (PEI), and polyallylamine
(PAH) as PSS 70,000/PEI 25,000/PSS/PEI/PSS/PAH. To
this, base magnetite/PAH/magnetite/PAH/magnetite/PAH
was attached using the layer-by-layer technique [30]. When
the first magnetic layer had been attached to the bubbles,
they were washed and separated in a magnetic field. This
procedure was repeated for each layer. The NOTA or the
DTPA was coupled covalently to the outmost PAH layer as
described previously to produce NOTA-SPION MBs or
Figure 3 Chemical structures of the ligands chitosan and PMMA.
Barrefelt et al. EJNMMI Research 2013, 3:12 Page 5 of 14
http://www.ejnmmires.com/content/3/1/12DTPA-SPION MBs. The incorporation of SPION was
determined to be 3.8 mg Fe/109 MBs/mL.
99mTc-MB synthesis
The reduced 99mTc is chemically reactive and can be
reacted with a chelating agent to become a 99mTc-che-
late. The chemical group –COO- is the electron donor
of DTPA and NOTA and NH2 is the electron donor of
chitosan as follows:
299mTcO4 þ 16Hþ 3Sn2þ⇔299mTc4þ þ 3Sn4þ þ 8H2O
Sodium pertechnetate (99mTc-NaTcO4) was obtained
from a 99Mo/99mTc generator. 99mTc was obtained using
the reducing agent stannous chloride SnCl2·2H2O
(Sigma-Aldrich Chemie GmbH, Munich, Germany).
MBs (0.2 mL of 108 MBs/mL) were diluted with 0.3 mL
of isotonic saline in 2-mL Eppendorf tubes (Eppendorf
AG, Hamburg, Germany). SnCl2·2H2O (0.5 mL) was
added to the MB solution at room temperature. 99mTc-
NaTcO4 (0.5 mL) with an activity of 1,000 to 1,500 MBq
(Dose Calibrator CRCW-15 PET, Capintec Inc., Pittsburgh,
PA, USA) was added to the ligand-functionalized MB-
SnCl2 solution for reduction reaction (5 min) at pH
5. The Eppendorf tubes were centrifuged (500 rpm, 4
min, Hettich Universal 16, Andreas Hettich GmbH &
Co. KG, Tuttlingen, Germany), and the subnatant was
removed. After centrifugation, isotonic saline was ad-
ded, and the procedure was repeated until radioacti-
vity in the subnatant was equal to or less than 5% of
the activity of MBs in the upper phase. To evaluate
the stability of labeled MBs, 0.2 mL (109 MBs/mL) of
DTPA-functionalized MBs and plain MBs were labe-
led as previously described using 60 MBq. The MBs
were washed until less than 5% remained in the subnatant.
The MBs were resuspended in saline, and the radioactivity
of the subnatant was followed for four 99mTc half-lives to
determine the leakage of 99mTc from the MBs.Analysis by instant thin-layer chromatography
Instant thin-layer chromatography (ITLC) was carried
out using an ITLC-SG silica gel (ITCLTM SG, Life
Sciences Advanced Technology Inc., St. Petersburg, FL,
USA) impregnated strip of 5 cm × 20 cm and acetone as
a mobile phase for 30 min. Equal volumes at 20 μL of
99mTc-labeled MBs and 99mTc-pertechnetate were placed
on the ITLC-SG strip and developed using acetone.
ITLC was evaluated by a gamma camera detector (Sie-
mens Symbia Vega, Siemens AG, Erlangen, Germany).
Cobalt pens were used as markers at Rf 0 (MBs), Rf 50
(0), and Rf 100 (
99mTc-NaTcO4). The strip was recorded
for 1 min with cobalt pens and 1 min without cobalt
pens. The ITLC strip was thereafter cut into eight pieces
which were numbered, and activity was measured in
each piece by the CRCW-15 PET dose calibrator
(Capintec, Inc.).
Animal studies
The study was approved by the Stockholm Southern
Ethical Committee on Animal Research and was per-
formed in accordance with Swedish Animal Welfare law.
Male Sprague Dawley rats weighing 300 ± 50 g were
purchased from Charles River (Charles River Laborator-
ies, Sulzfeld, Germany). After arrival, the animals were
allowed to acclimatize for at least 1 week in the animal
facility before the start of the experiment. The animals
were given access to food and water ad libitum, 12-h
light/dark cycle, controlled humidity (55 ± 5%), and
temperature (21 ± 2°C). The rats were anesthetized
using an intraperitoneal injection of pentobarbital (so-
dium pentobarbital 60 mg/mL, APL Kungens Kurva,
Sweden) at a dose of 50 mg/kg. Hybrid imaging was
performed following an intravenous injection of 0.5 mL
MBs via the tail vein on freely breathing rats using
SPECT/CT, followed by 3-T MRI. Animals were injected
with 0.5 mL 99mTc-labeled plain, DTPA, chitosan,
PMAA, NOTA, NOTA-SPION, or DTPA-SPION MBs.
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functionalized with PMAA, chitosan, or DTPA received
a dose of 10 to 20 MBq, while rats to be imaged with
MRI and SPECT and followed for 24 h received a dose
of 100 to 150 MBq. Two rats were used for a pilot study
to set up the imaging parameters, and two rats were used
to study each ligand-functionalized MB sample. Free so-
dium pertechnetate (99mTc-NaTcO4) was obtained from
the 99Mo/99mTc generator, injected, and imaged as a
reference. 99mTc-DTPA without attachment to MBs was
also injected as a reference to visualize the DTPA distribu-
tion compared to MBs functionalized by DTPA.
In the second part of the study, rats were injected with
plain MBs and MBs functionalized with PMAA, NOTA,
chitosan, or DTPA. Each animal received a dose of 10 to
20 MBq (n = 4 for each MB): two were sacrificed at 11.7
min (time for regions of interest (ROI) measurement),
and two were sacrificed 1 h post injection. Rats were
injected with NOTA-SPION MBs (n = 6) or DTPA-
SPION MBs (n = 6) at a dose of 100 to 150 MBq. Two
rats per MB were sacrificed at 11.7 min, two were
sacrificed at 1 h, and two were sacrificed at 24 h. The
liver, lungs, spleen, bladder, kidneys, and blood were
removed, and radioactivity was measured.
Nuclear medicine imaging
SPECT/CT imaging was performed using a Siemens
Symbia True Point 16 hybrid system (SymbiaW Siemens,
Erlangen, Germany) with parallel hole LEHR collimators.
Dynamic planar scintigraphy and SPECT/CT
Initially, the animals were placed in prone position in
the gamma camera. The 99mTc-labeled functionalized
MBs, 99mTc-pertechnetate, and 99mTc-TechneScanW
DTPA (99mTc-DTPA kit) (Mallinckrodt, Hazelwood,
MO, USA) were injected intravenously into the tail vein
during dynamic planar scintigraphy (two frames per sec-
ond) for a total duration of 11.4 to 11.7 min. The matrix
size used was 256 × 256 with a suitable energy window
for 99mTc (15% wide). To follow the distribution and
clearance of SPION MBs using MRI and SPECT/CT, the
animals injected with NOTA-SPION MBs and DTPA-
SPION MBs were additionally imaged using dynamic
planar scintigraphy 24 h post injection. Directly after dy-
namic scintigraphy, SPECT was performed for all animals
injected with 99mTc-labeled ligand-functionalized MBs,
99mTc-DTPA kit, and 99mTc-NaTcO4. Animals injected
with NOTA MBs, NOTA-SPION MBs, and DTPA-SPION
MBs were also imaged 24 h post injection using SPECT/
CT. The SPECT parameters used were 128 × 128 matrix,
64 projections over 360°, noncircular orbit, step-and-shoot
mode. The duration of each projection was 60 s. The
acquisition time required for SPECT was 32 min. Im-
mediately after the SPECT acquisition, a CT scan wasperformed with a tube current of 110 kV, quality reference
milliampere second was 160 mA s, and modulated with
CareDose4DW; rotation time was 0.6 s, and pitch was 1.0.
Subsequently, the CT data were reconstructed with a slice
thickness of 0.75 mm and a “B70s sharp” kernel. Recon-
struction of the SPECT data and evaluation of the
resulting images were made on a Hermes workstation
(Hermes Medical Solutions AB, Stockholm, Sweden). It-
erative reconstruction was made with ordered subset ex-
pectation maximization (four iterations, eight subsets,
including resolution recovery). A 3D Gaussian post filter
(0.8 cm FWHM) was finally applied.
Evaluation
ROIs were outlined for the organs on the dynamic
images, and counts were measured in each ROI. No cor-
rection for radioactive decay was made due to the short
time interval. The number of counts in each organ was
compared to the total counts in the whole animal to ob-
tain the percentage of distribution to each organ. Inter-
pretation of fused SPECT/CT images was made in three
orthogonal planes. To establish the values obtained from
ROIs, animals were sacrificed, organs were removed, and
radioactivity was measured. The radioactivity in organs
was compared to the total injected dose.
Magnetic resonance imaging
Rats injected with NOTA-SPION MBs and DTPA-
SPION MBs were first imaged using SPECT/CT and
then brought to the 3-T MRI scanner (Siemens Trio,
Siemens, Erlangen, Germany) for imaging. The animals
were put head first in prone position in an extremity
coil. Imaging was performed using a gradient echo T2*
sequence to obtain images with a fixed repetition time
of 2,000 ms and 12 stepwise increasing echo times (TEs)
of 2 to 22.9 ms. Field of view was 250 mm with a phase
encoding of 59.4% and a slice thickness of 3 mm. Circu-
lar ROIs were placed in the respective organs, and the
negative logarithmic values of signal intensities at diffe-
rent TEs were plotted versus respective TE values
followed by calculation of T2*. In the organs with short
T2* (i.e., the liver after injection of NOTA-SPION MBs
and DTPA-SPION MBs), the calculations were based on
fewer measurement points, excluding those with long
TEs where full transaxial relaxation had already oc-
curred. The rats were imaged using 3-T MRI before in-
jection of MBs (reference value), approximately 2 and 24
h post injection of the 99mTc-labeled NOTA-SPION
MBs and DTPA-SPION MBs.
Results and discussion
Results
The 99mTc labeling yield of MBs was dependent on
the functional ligand attached to the MBs. The labeling
Figure 4 Dynamic distribution in rat organs within the first 11.7 min post injection of 99mTc-DTPA kit and 99mTc-labeled MBs. Designated
colors for organs: lungs (red), liver (yellow), bladder (turquoise), kidneys (maroon). (A) DTPA kit. (B) Plain MBs. (C) DTPA MBs. (D) Chitosan MBs.
(E) PMAA MBs. (F) NOTA MBs.
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activity at the start) after 99mTc labeling, purification,
and washing steps were in the following order: MBs
functionalized with DTPA, 60%; MBs functionalized with
PMAA, 45%; MBs functionalized with NOTA, 42%;
and MBs functionalized with chitosan, 25%; while theTable 1 Percentage of radioactivity found in organs expresse
MBs ROI measurements as




Lungs Liver Kidneys Lungs
Plain 69 25 3 67
DTPA 62 28 7 66
Chitosan 64 28 3 58
PMAA 58 34 8 57
NOTA 43 37 8 50
NOTA-SPION 56 24 8 51
NOTA-SPION(24 h, PI) 8 50 18
DTPA-SPION 93 4 1 89
DTPA-SPION(24 h, PI) 25 40 40labeling of plain MBs yielded about 20%. The labeling
yield was 85% for MBs with DTPA-SPION and 52% for
MBs with NOTA-SPION. No precipitate was observed
after 99mTc labeling and washing. The radiochemical
purity of the washed and purified MBs was equal to or
above 95% as determined by the dose calibrator. Thesed as ROI/total counts and radioactivity/injected dose
tal radioactivity in organs as percentage of injected dose
11.7 min 1 h
Liver Kidneys Lungs Liver Kidneys
32 2 59 36 8
25 5 52 43 6
22 2 51 39 5
35 4 48 43 7
40 3 47 45 6
23 4 60 20 6
6a 54a 16a
6 1 65 38 7
21a 37a 41a
Figure 5 Coronal SPECT/CT fusion images illustrating the uptake of 99mTc-pertechnetate and 99mTc-labeled MBs in rats. (A) 99mTc-
pertechnetate, (B) plain MBs, (C) DTPA MBs, (D) chitosan MBs, (E) PMAA MBs, and (F) NOTA MBs, 1 h post injection. (G) NOTA MBs, liver view,
24 h post injection. (H) NOTA MBs, kidney view, 24 h post injection.
Figure 6 Dynamic distribution in rat organs within the first 11.7 min and 24 h post injection of 99mTc-labeled NOTA-SPION and DTPA-
SPION MBs. Designated colors for organs: lungs (red), liver (yellow), bladder (turquoise), and kidneys (maroon). (A) NOTA-SPION MBs during the
first 11.7 min post injection. (B) NOTA-SPION MBs 24 h post injection. (C) DTPA-SPION MBs during the first 11.7 min post injection.
(D) DTPA-SPION MBs 24 h post injection.
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Figure 7 Coronal fusion SPECT/CT images and 3-T MRI T2* images illustrating the uptake of 99mTc-labeled NOTA-SPION MBs in rats. (A)
3-T MRI pre-injection. (B) SPECT/CT, 1 h post injection. (C) 3-T MRI, 2 h post injection. (D) SPECT/CT, 24 h post injection. (E) 3T MRI, 24 h
post injection.
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in vitro studies showed that labeled MBs resuspended in
saline were stable (no significant leakage was detected).
Considering the radioactivity decay, 6.25% of the initial
radioactivity should remain. After 24 h (four half-lives),
we detected 5.4% of the initial radioactivity in MBs, indi-
cating the stability of the labeling. Figure 4 represents
the dynamic distribution of 99mTc-labeled MBs with dif-
ferent ligands; the values are summarized in Table 1. As
can be seen in Figure 4A, a rapid uptake by the kidneys
occurs during the first 2 min followed by a slow decline
up to 11.7 min. After 2 min, the radioactivity was
eliminated from the kidneys and accumulated in the
bladder. Figure 4B shows the dynamic distribution ofplain MBs: the uptake was about 69% in the lungs, 25%
in the liver, and less than 5% in the kidneys (Table 1).
DTPA MBs (Figure 4C) were mainly distributed to the
lungs (62%), while 28% of the uptake was observed in the
liver, and less than 10% was found in the kidneys
(Table 1). Uptake of chitosan MBs (Figure 4D) was
observed mainly in the lungs (64%), while about 28% was
distributed to the liver, and <10% was observed in both
bladder and kidneys (Table 1). Figure 4E illustrates the
dynamic distribution of MBs functionalized with PMAA:
58% of the injected radioactive tracer was distributed to
the lungs within the first minute, while the distribution
to the liver reached 34% within the first 2 min, and less



























Figure 8 MR signal decay in various organs. MR signal decay in
the liver (A) and in the kidneys (B) of the rat before (black circle), 2 h
(triangle), and 24 h (black diamond) post injection of NOTA-SPION
MBs and DTPA-SPION MBs based on ROI measurements.
Barrefelt et al. EJNMMI Research 2013, 3:12 Page 10 of 14
http://www.ejnmmires.com/content/3/1/12MBs (Figure 4F) were rapidly distributed to the lungs,
with the highest uptake within less than 1 min (43%).
Within 3 min, the activity had declined in the lungs, and
it reached a steady state at 3 min post injection. Distribu-
tion to the liver (37%) was reached within the first mi-
nute; about 8% was found in the kidneys, and less than
5% was found in the bladder (Table 1). These results were
confirmed by removing the organs and measuring the
radioactivity in each organ at 11.7 min and 1 h for all
MBs, and at 24 h post injection of NOTA MBs and
DTPA-SPION MBs (Table 1). The results are expressed
as (ratio of radioactivity in organ/injected dose × 100).
Moreover, less than 3% of the total injected dose was
detected in the blood, and no radioactivity was detected
in the bladder/urine.
The distribution of radioactivity to different organs was
expressed either as ROI measurements (as percentage of
the total counts obtained from dynamic imaging at 11.7
min) or as radioactivity measured in organs (as percentage
of the total injected dose after 11.7 min and after 1 h post
injection). aValues measured at 24 h.
Figure 5 illustrates the fusion SPECT/CT images for
free 99mTc-pertechnetate and MBs functionalized with
different ligands. The distribution of free 99mTc-
pertechnetate (Figure 5A) post injection shows that the
radioactivity was distributed from highest to lowest in
the following order: stomach, bladder, thyroid gland, thy-
mus, liver, and mouth mucosal membrane. The distribu-
tion of plain MBs was mainly to the lungs and, to a lesser
extent, to the liver, spleen, and kidneys (Figure 5B).
The addition of DTPA as a ligand to MBs affects the
distribution, as can be seen in Figure 5C. DTPA MBs
were mostly observed in the lungs, followed by the liver
and spleen. No distribution to other organs could be
detected. Similar distribution was seen after the adminis-
tration of chitosan MBs (Figure 5D). PMAA MBs were
also distributed mainly to the lungs and liver (Figure 5E).
However, a higher distribution was seen in the liver
compared with that observed for DTPA MBs and
chitosan MBs. NOTA MBs were distributed mainly to
the lungs and, to a lesser extent, to the liver, followed by
the spleen, kidneys, and bladder (Figure 5F). After 24 h,
NOTA MBs were mainly located in the liver, stomach,
and kidneys (Figure 5G,H). NOTA MBs and NOTA-
SPION MBs showed a different distribution pattern at
dynamic imaging compared with the other MB types
described in this study (Figures 4F and 6A). After 11.7
min, the highest uptake of NOTA-SPION MBs was ob-
served in the lungs (56%), followed by the liver (24%), and,
to a lesser extent, the kidneys (8%), and the bladder (<5%)
(see Figure 6A). After 24 h post injection, the activity had
been redistributed so that the main activity was located in
the liver (50%) and, to a lesser extent, in the kidneys
(18%), lungs (8%), and bladder (<5%) (see Figure 6B).DTPA-SPION MBs showed a rapid and exclusive dis-
tribution to the lungs at 11.7 min post injection (93%)
(Figure 6C). After 24 h, redistribution of radioactivity
was observed in the liver (40%), kidneys (40%), and lungs
(25%) as can be observed in Figure 6D.
Figure 7A shows MR image pre-injection. As shown in
the fusion SPECT/CT image (Figure 7B), a high uptake
was observed in the lungs, while a lesser uptake was seen
in the liver, kidneys, and bladder. Because it is a dual con-
trast agent, the distribution of NOTA-SPION MBs to the
liver could also be confirmed by MRI, in which the signal
of the liver was markedly decreased 2 h post injection
(Figure 7C) compared with that prior to injection
(Figure 7A). After 24 h post injection, the radioactivity
was redistributed mainly to the liver and spleen (Figure
7D) and, in a lower amount, to the kidneys. The accumu-
lation in the liver was confirmed using MRI (Figures 7E
and 8A). Based on the ROI measurements in both the
liver and kidneys using MRI, the T2* of the liver decreased
by 79% 2 h post injection and by 82% 24 h post injection
(Figure 8A). A 50% T2* decrease was calculated 2 h post
injection in the kidneys, while it had decreased by 64% 24
h post injection (Figure 8B). The SPECT and MR images
were fused for rats injected with DTPA-SPION MBs
(Figure 9), visualizing the concept of multimodality
Figure 9 Multimodality imaging using SPECT/MRI. SPECT enables the functional visualization of MBs in the lungs 1 h post injection (A) and in
the liver and kidneys 24 h post injection (B), while MRI enables the visualization of an anatomical image and SPION in the liver post injection and
24 h post injection (A and B).
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sively enables the visualization of MBs in the lungs 1 h
post injection (Figure 9A) and in the liver and kidneys 24
h post injection (Figure 9B).
Discussion
In the present study we successfully labeled the newly
developed MBs with 99mTc using DTPA, chitosan,
PMAA, and NOTA. The labeling yield of MBs was
affected by the attached ligand but was also seen in plain
MBs. The highest labeling yield was observed in MBs
functionalized with DTPA, followed by PMAA, and
NOTA. The fact that plain MBs as well as PMAA and
NOTA MBs could also be labeled by 99mTc, but to a
lesser extent, most probably indicates that 99mTc was
incorporated into the PVA matrix of the bubbles by
nonspecific binding.
The distribution of MBs, as observed using dynamic
planar scintigraphy and SPECT/CT, was affected by the
attached ligands. DTPA, chitosan, and PMAA MBs were
mainly distributed to the lungs and, to some extent, to
the liver, while NOTA MBs were evenly distributed to
the lungs and the liver. Moreover, uptake was observed
in the kidneys after administration of PMAA MBs,
NOTA MBs, and NOTA-SPION MBs. This is most
probably due to free 99mTc liberated in vivo from the
MBs and eliminated mainly through the kidneys. In anin vitro test using labeled MBs resuspended in saline, a
nonsignificant amount of 99mTc had been released from
the MBs 10 and 30 min and 1, 3, and 24 h after 99mTc
labeling. Another possible explanation for the activity
observed in the kidneys is that some of the MBs might
burst in vivo and fragments carrying 99mTc might then
be eliminated via the kidneys. After 24 h, the NOTA-
SPION MBs were redistributed from the lungs to the
liver and kidneys. Moreover, measuring the radioactivity
in isolated organs after injecting different 99mTc-labeled
MBs was in good agreement with the results obtained
from the gamma camera and SPECT.
SPECT/CT imaging of animals injected with NOTA-
SPION MBs demonstrated major distribution to the
lungs and, to a lesser extent, to the liver and kidneys,
while the MBs had been redistributed mainly to the liver
24 h post injection. Actually, radioactivity was no longer
visually observed in the lungs, while it was still visible in
the kidneys and spleen. Co-registration of NOTA-
SPION MBs using 3-T MRI assessed 2 and 24 h post in-
jection confirmed a considerable increase in liver uptake
with concomitant canceling of the MRI signal during the
first 24 h. The uptake of 99mTc- labeled DTPA-SPION
MBs was observed in the lungs 1 h post injection using
SPECT, while the redistribution to the liver and kidneys
was seen on SPECT-MR images 24 h post injection.
SPECT images obtained 1 h post injection as well as 24
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showed that MBs and SPION can be utilized for mul-
timodality imaging.
To establish the distribution of 99mTc-labeled MBs, a
reference containing free 99mTc-pertechnetate was
injected into the rat, and the distribution of radioactivity
was scanned using SPECT/CT. The distribution of
99mTc differed from that obtained after injection of the
99mTc-labeled MBs. In rats injected with free 99mTc-
pertechnetate, the distribution was mainly to the stom-
ach, kidneys, and bladder (Table 1). Some radioactivity
was also observed in the thymus, thyroid gland, and
mouth mucosal membranes. The different distribution
observed after free 99mTc-pertechnetate and 99mTc-la-
beled MBs indicates that no free 99mTc was present
when injecting 99mTc-labeled MBs. Radioactivity in the
respective organs, measured by drawing ROIs on dy-
namic images, was in agreement with the visual evalu-
ation of SPECT/CT images.
The high distribution of MBs into the lungs might be
due to their size, lipophilicity, or building of aggregates
with a diameter larger than 5 μm, causing them to be
trapped in the capillary bed in the lungs. However, after
24 h, an accumulation of radioactivity was observed in
the liver, which is most probably due to an uptake of
MBs by the Kupffer cells. The fragments of the MBs
might then be metabolized and eliminated through the
kidneys and bladder as observed by SPECT/CT. It is also
possible that this could be caused by the release of
99mTc-pertechnetate in vivo from the ligands and/or
through leakage from the PVA matrix over time.
99mTc-tin colloids have been used as a radio-
pharmaceutical to measure the liver function. Kyung
et al. injected both pigs and rats with 99mTc-tin colloids
to follow its biodistribution. The authors concluded
from their investigation that in small animals (rats), the
99mTc-tin colloids distributed exclusively to the liver dir-
ectly post injection, while the distribution of colloids in
the large animals (pigs) was observed in the lungs
[31,32]. This, together with our results, indicates that
our labeled MBs did not contain colloids due to the
observed distribution to the lungs within the first hour.
Moreover, most of the colloids could have been removed
from the MBs through the several washing and centrifu-
gation steps.
The use of SPION has been reported in several stud-
ies. Madru et al. reported that 99mTc-labeled SPION was
used to visualize lymph nodes in rats using SPECT/CT
and MRI [7]. The authors also showed that SPION may
be used both for MR as well as SPECT imaging when
labeled by 99mTc. In our study, the NOTA MBs
containing SPION that were co-registered using SPECT/
CT and MRI were mainly distributed to the lungs imme-
diately post injection and redistributed to the liver andkidneys after 24 h. Lazarova et al. [4] labeled lipid shell
ultrasound microbubbles from Visualsonics with 99mTc
and injected them into Wistar rats. The authors reported
that the lipid MBs were accumulated in the liver and
spleen after 4 and 60 min post administration. Using
ultrasound contrast, it has also been demonstrated that
not only the size, but also the surface architecture of the
bubble influences the circulating time [33]. In the
current study, the distribution was initially observed in
the lungs after 60 min, but over time, radioactivity was
gradually redistributed to the liver and spleen as well as
to the kidneys and bladder. The different distribution
pattern might be explained both by different MB com-
position and the attached ligands. One of the important
factors for distribution is the amine content. It was re-
cently demonstrated that the lung uptake was consider-
ably increased by amine modifications [34]. Another
factor that may influence adhesion properties, uptake,
and impact on cells of MBs is the generation of a protein
corona around nanoparticles [35] and MBs [36].
Conclusions
In conclusion, fusion SPECT/CT imaging of 99mTc-la-
beled MBs with various ligands is an appropriate way to
study biodistribution and elimination in vivo. Moreover,
incorporating SPION between the layers in MBs enables
co-registration and multimodal imaging using SPECT/
MRI and SPECT/CT. Each imaging technique gives an
extra dimension to the information on biodistribution,
elimination, and physiological status that enhances the
interpretation of data. This in turn may increase the use-
fulness of multimodality in preclinical and clinical prac-
tice. A high labeling yield of DTPA-SPION MBs as well
as their suitability for multimodal imaging SPECT/CT/
MRI favor these MBs for further studies as a candidate
for drug delivery of cytostatics and imaging of cancers
such as lung cancer, HCC, or metastasis. Sufficient label-
ing yield of NOTA MBs, in combination with distribu-
tion to several organs including the lungs, liver and
kidneys, favors this ligand as a candidate for future stud-
ies using PET. Further, the low lung-to-liver ratio after
24 h when using NOTA-SPION MBs indicates that the
stiffening of MBs that is probably caused by the loading
of SPION does not obstruct the redistribution from the
pulmonary circulation to the liver.
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